Revvity, Inc.
RVTY is executing better, but $140.19 already prices in a much stronger and cleaner growth path than management has actually guided, leaving a stock on 61.2x FY2025 EPS with leverage still elevated at 5.04x debt/EBITDA.
RVTY is not a broken company. It is an expensive one. The business has regained some momentum, particularly in Diagnostics, and management has earned back some credibility with 8 straight quarterly EPS beats, a raised FY26 outlook, and a clear statement that backlog entering Q3 is the strongest seen in the last 3 to 4 years. Q2 was undeniably good: $711M in revenue, 3% organic growth slightly above the high end of guidance, $1.41 adjusted EPS versus $1.21 expected, and 29.3% adjusted operating margin versus a 27% outlook.
The problem is that the stock already discounts a much cleaner acceleration. At $140.19, RVTY trades on 61.2x FY2025 EPS and 4.93x sales, both well above peer averages of 25.9x and 3.2x. Even giving management credit for the FY26 reset to $5.30-$5.40 adjusted EPS, investors are still paying about 26x forward adjusted earnings for a company guiding just 4%-5% organic growth. That is not absurd for a high-quality diagnostics compounder with low leverage and strong recurring revenue. It is hard to defend for a company with 5.04x debt/EBITDA, FY2025 operating margin down to 13.5% from 14.9%, and free cash flow of just $0.2B in FY2025.
The short case depends on three things. First, Diagnostics strength has to stop being extrapolated into a whole-company growth breakout when Life Sciences was still -3% organic in Q2. Second, investors need to separate clean execution from temporary help. Q2 included $16M in tariff refunds and tax timing, and management already flagged that the tax benefit reverses in Q4. Third, the stock's setup matters. Shares are 35.8% above the 200-day average, up 41.55% in three months, and essentially at the 52-week high of $140.22. That is where any miss on Q3 organic growth, software recovery, or margins can matter far more than it would at $90.
What keeps conviction at Medium rather than High is that execution is genuinely better and the backlog commentary is strong. If Q3 and Q4 convert that demand into sustained 4%-6% growth without one-time assists, the downside case weakens. Until then, the stock price is ahead of the fundamentals.
Diagnostics remains near double-digit growth, software reaccelerates in 2H, and investors keep rewarding the cleaner recovery with a premium multiple.
Execution remains decent, but modest growth and elevated leverage cannot support a stock still priced above the engine's blended fair value.
Life Sciences stays weak, one-time Q2 benefits unwind, and the stock de-rates toward a lower multiple on sub-5% growth.
Quant call (SELL) diverges from analyst consensus (Strong Buy: 4 buy / 3 hold / 0 sell) — resolve explicitly.
The four most dangerous words in investing are: 'this time it's different.'
Forward earnings power is better than the FY2025 GAAP-looking base suggests, but even on management's $5.30-$5.40 adjusted EPS outlook the stock trades at roughly 26x forward earnings, hardly cheap for a company guiding just 4%-5% organic growth and carrying 5.04x debt/EBITDA. The moat still exists in diagnostics workflows, installed instruments, assay menus, and regulated lab relationships, but over the next 3-5 years it looks more solid than widening, because software and informatics need to prove they can convert AI into durable pricing power rather than just feature parity. AI is a modest tailwind in image analysis, workflow software, and screening productivity, but it is not likely to transform RVTY into a structurally faster grower; regulation and reimbursement still matter more in diagnostics, and instrument cycles remain exposed to pharma and China demand. At this price, the market is paying for a stronger secular story than the company has yet demonstrated.
- 61.2x FY2025 EPS and 4.93x sales versus peer averages of 25.9x P/E and 3.2x P/S
- FY26 guide implies only 4%-5% organic growth, $2.83B-$2.86B revenue, and $5.30-$5.40 adjusted EPS
- Balance sheet remains stretched at 5.04x debt/EBITDA with FY2025 FCF only $0.2B
- Management raised FY26 organic growth to 4%-5% from 3%-4%, with CEO stating, "Consequently, we are now expecting total company organic growth this year of 4% to 5%, up from our prior 3% to 4% outlook."
- Q2 execution was strong: $711M revenue, 3% organic growth, $1.41 adjusted EPS versus $1.21 street, and 29.3% adjusted operating margin versus the 27% outlook.
- Diagnostics is carrying the story, up 11% organic in Q2, while high-content screening order velocity exceeded production capacity and built backlog into 2H.
- The earnings track record is credible, with 8 straight EPS beats, including +16.5%, +8.3%, and +13.3% beats in the last eight quarters.
- The valuation is extreme for the growth on offer: 61.2x P/E on FY2025 EPS and peer dispersion is wide at 3.7x, weakening the case that peer multiples justify the stock.
- FY2025 fundamentals were not strong enough to support this price, with revenue up only 1.8% YoY and operating margin down to 13.5% from 14.9%.
- Q2 upside was not fully clean. Management cited $16M tariff refunds and tax timing, and specifically noted that the tax benefit reverses in Q4.
- Life Sciences remains uneven, down 3% organic in Q2, with software off about 20% on contract timing and capacity constraints still limiting upside.
| Metric | Value | Context |
|---|---|---|
| Current price | $140.19 | Engine price target implies -39.7% downside |
| Price target | $84.57 | Low confidence, basis earnings_growth_blend |
| FY2025 revenue | $2.9B | +1.8% YoY, modest growth against premium valuation |
| FY2025 EPS | $2.08 | +13.5% YoY, but valuation still stretched |
| FY2025 operating margin | 13.5% | Down from 14.9% in the prior year |
| Valuation | P/E 61.2x | P/S 4.93x | P/B 1.99x | Versus peer averages 25.9x P/E and 3.2x P/S |
| Leverage | Debt/Equity 0.46 | Debt/EBITDA 5.04x | Elevated leverage for a company guiding mid-single-digit organic growth |
| Liquidity and cash flow | Current ratio 1.80 | FCF $0.2B | Adequate liquidity, but cash generation is not strong enough to make valuation easy |
| FY26 guidance | Revenue $2.83B-$2.86B | Adjusted EPS $5.30-$5.40 | Organic growth 4%-5%, adjusted operating margin 28.7% |
| Latest quarter | Q2 FY26 revenue $711M | adj. EPS $1.41 | EBITDA $0.19B | Organic growth 3%, EBITDA margin 25.8% |
| Price action | 1M +19.31% | 3M +41.55% | 52-week high $140.22 | Current price is -0.0% vs high and 35.8% above 200-day average |
The biggest risk to a bearish stance is that Diagnostics sustains double-digit growth and Life Sciences rebounds fast enough for investors to look through the current 61.2x multiple.
Next catalyst is Q3/FY26 earnings on October 26, 2026, where investors need to see whether 4%-6% Q3 organic growth and $685M-$700M revenue guidance hold without another large one-time benefit.
Ownership is very concentrated, with the top three institutions at 95.4% and insiders just 0.4%, which can amplify moves when expectations shift. Short interest is not extreme but meaningful at 6.17%, or 6.3M shares and 4.1 days to cover, so there is some squeeze fuel, especially after the stock's 41.55% three-month move. Options positioning is flagged as positive gamma, which usually dampens near-term volatility rather than signaling a fresh upside squeeze setup.
Q2 FY26 organic growth was +11%, with strength across reproductive health and immunodiagnostics ex-China.
Q2 FY26 organic growth was -3%, hurt by a roughly 20% software decline on contract timing and tough comps.
China has remained a drag in instruments since the 2024 period, and the company has a definitive agreement to divest China immunodiagnostics by end-2027.
Q2 beat and FY26 guide raised on improving pharma/biotech demand and Diagnostics strength.
Management's execution is mixed but improving. In the 2024 Q3 call, the company cut FY24 organic growth to 0%-1%, guided adjusted operating margin to 28.0%-28.5%, adjusted EPS to $4.83-$4.87, and free cash flow to about $550M, while acknowledging that "the path to normalization may take a little longer than previously expected" because instruments, especially in China, were weak. Since then, the company has delivered a strong beat cadence with 8 straight EPS beats, and the latest 2026 Q2 call showed enough improvement for management to raise FY26 organic growth to 4%-5% and adjusted EPS to $5.30-$5.40. That said, the strategy has not changed dramatically. It is still the same playbook of diagnostics resilience offsetting uneven life sciences demand, now helped by ACD/Labs and some better pharma/biotech spending. Credibility is decent on margins and EPS, but less strong on clean growth quality because Q2 included one-time tax timing and $16M of tariff refunds, while Life Sciences still posted -3% organic growth.
Consequently, we are now expecting total company organic growth this year of 4% to 5%, up from our prior 3% to 4% outlook.
This all results in our updated full year adjusted EPS outlook to now be in a range of $5.30 to $5.40, which is up $0.10 from our prior guidance.
Overall, our adjusted operating margins were 29.3% in the quarter, well above our 27% outlook.
I would say starting 3Q from probably the strongest position that we have seen in terms of backlog we've had in the past 3 to 4 years.
For the third quarter, we expect our organic growth to be in the 4% to 6% range. Assuming FX rates as of the end of June and the incremental contribution from the ACD/Labs acquisition, this puts our expected revenue for the third quarter in the range of $685 million to $700 million.
RVTY's edge comes from embedded diagnostic workflows, regulated assay portfolios, recurring consumables, and customer switching costs once instruments and software are installed in labs. That moat is still real, particularly in reproductive health and immunodiagnostics, but it is not impregnable. Over the next few years its durability depends on whether software, high-content screening, and ACD/Labs integration deepen workflow lock-in faster than competitors narrow the gap with AI-enabled analytics.
Capital deployment has been conservative lately because leverage needs to come down. FY2025 free cash flow was only $0.2B, and deep-dive data shows $0.0B for buybacks, dividends, and capex, which implies management is prioritizing balance-sheet repair and integration over returning cash. That is sensible with 5.04x debt/EBITDA, but it also limits near-term per-share support despite the old $1B repurchase authorization approved in 2024.
Rated SELL, Medium conviction. RVTY is executing better than it was two years ago, but the stock has already repriced that improvement and then some. A company guiding 4%-5% organic growth and carrying 5.04x debt/EBITDA should not comfortably command 61.2x FY2025 EPS at the 52-week high. The bearish call would change if the company proves that Diagnostics strength can lift whole-company growth sustainably above the current guide while Life Sciences recovers without one-time earnings support. Until that evidence is in the numbers, the stock looks priced for more than the business has earned.
≣ Full research note tap to expand
Executive Summary
SELL, Medium conviction. Rated SELL, Medium conviction. The business has clearly improved, with FY26 guidance raised to 4%-5% organic growth and $5.30-$5.40 adjusted EPS, but the stock now sits essentially at its 52-week high after a 41.55% three-month run and trades far above both peers and the engine's $84.57 base value. The issue is not operations alone. It is that modest growth, one-time Q2 help from $16M tariff refunds and a rich multiple leave little margin for error.
Investment Thesis
RVTY is not a broken company. It is an expensive one. The business has regained some momentum, particularly in Diagnostics, and management has earned back some credibility with 8 straight quarterly EPS beats, a raised FY26 outlook, and a clear statement that backlog entering Q3 is the strongest seen in the last 3 to 4 years. Q2 was undeniably good: $711M in revenue, 3% organic growth slightly above the high end of guidance, $1.41 adjusted EPS versus $1.21 expected, and 29.3% adjusted operating margin versus a 27% outlook.
The problem is that the stock already discounts a much cleaner acceleration. At $140.19, RVTY trades on 61.2x FY2025 EPS and 4.93x sales, both well above peer averages of 25.9x and 3.2x. Even giving management credit for the FY26 reset to $5.30-$5.40 adjusted EPS, investors are still paying about 26x forward adjusted earnings for a company guiding just 4%-5% organic growth. That is not absurd for a high-quality diagnostics compounder with low leverage and strong recurring revenue. It is hard to defend for a company with 5.04x debt/EBITDA, FY2025 operating margin down to 13.5% from 14.9%, and free cash flow of just $0.2B in FY2025.
The short case depends on three things. First, Diagnostics strength has to stop being extrapolated into a whole-company growth breakout when Life Sciences was still -3% organic in Q2. Second, investors need to separate clean execution from temporary help. Q2 included $16M in tariff refunds and tax timing, and management already flagged that the tax benefit reverses in Q4. Third, the stock's setup matters. Shares are 35.8% above the 200-day average, up 41.55% in three months, and essentially at the 52-week high of $140.22. That is where any miss on Q3 organic growth, software recovery, or margins can matter far more than it would at $90.
What keeps conviction at Medium rather than High is that execution is genuinely better and the backlog commentary is strong. If Q3 and Q4 convert that demand into sustained 4%-6% growth without one-time assists, the downside case weakens. Until then, the stock price is ahead of the fundamentals.
Key Metrics
| Metric | Value | Context | ||
|---|---|---|---|---|
| Current price | $140.19 | Engine price target implies -39.7% downside | ||
| Price target | $84.57 | Low confidence, basis earnings_growth_blend | ||
| FY2025 revenue | $2.9B | +1.8% YoY, modest growth against premium valuation | ||
| FY2025 EPS | $2.08 | +13.5% YoY, but valuation still stretched | ||
| FY2025 operating margin | 13.5% | Down from 14.9% in the prior year | ||
| Valuation | P/E 61.2x | P/S 4.93x | P/B 1.99x | Versus peer averages 25.9x P/E and 3.2x P/S |
| Leverage | Debt/Equity 0.46 | Debt/EBITDA 5.04x | Elevated leverage for a company guiding mid-single-digit organic growth | |
| Liquidity and cash flow | Current ratio 1.80 | FCF $0.2B | Adequate liquidity, but cash generation is not strong enough to make valuation easy | |
| FY26 guidance | Revenue $2.83B-$2.86B | Adjusted EPS $5.30-$5.40 | Organic growth 4%-5%, adjusted operating margin 28.7% | |
| Latest quarter | Q2 FY26 revenue $711M | adj. EPS $1.41 | EBITDA $0.19B | Organic growth 3%, EBITDA margin 25.8% |
| Price action | 1M +19.31% | 3M +41.55% | 52-week high $140.22 | Current price is -0.0% vs high and 35.8% above 200-day average |
Financial Strength
The balance sheet is not distressed, but it is not a source of upside either. A 1.80 current ratio gives the company room to operate, yet 5.04x debt/EBITDA is high for a business growing low single digits to mid single digits organically, and FY2025 free cash flow of $0.2B is light relative to $3.3B of debt. Margin quality is also split between reported and adjusted views: FY2025 operating margin fell to 13.5%, while adjusted quarterly profitability remains much better near the high 20s. That gap is manageable if growth continues improving, but it weakens the case for paying such a large premium multiple today.
Competitive Position
RVTY's edge comes from embedded diagnostic workflows, regulated assay portfolios, recurring consumables, and customer switching costs once instruments and software are installed in labs. That moat is still real, particularly in reproductive health and immunodiagnostics, but it is not impregnable. Over the next few years its durability depends on whether software, high-content screening, and ACD/Labs integration deepen workflow lock-in faster than competitors narrow the gap with AI-enabled analytics.
Management & Guidance
Management is guiding FY26 organic growth of 4%-5%, revenue of $2.83B-$2.86B, adjusted operating margin of 28.7%, and adjusted EPS of $5.30-$5.40, with Q3 revenue at $685M-$700M and organic growth of 4%-6%. That guidance looks credible on cadence because the company has beaten EPS estimates in each of the last 8 quarters, and Q2 exceeded the high end of revenue, margin, and EPS guidance. The caution is that part of Q2's upside came from tariff refunds and tax timing, while Life Sciences still has uneven demand and some capacity constraints remain, so guidance is credible but not clean enough to justify ignoring valuation risk.
Segment Analysis
- Diagnostics (N/A): Q2 FY26 organic growth was +11%, with strength across reproductive health and immunodiagnostics ex-China.
- Life Sciences (N/A): Q2 FY26 organic growth was -3%, hurt by a roughly 20% software decline on contract timing and tough comps.
- Geography: China exposure (N/A): China has remained a drag in instruments since the 2024 period, and the company has a definitive agreement to divest China immunodiagnostics by end-2027.
Capital Allocation
Capital deployment has been conservative lately because leverage needs to come down. FY2025 free cash flow was only $0.2B, and deep-dive data shows $0.0B for buybacks, dividends, and capex, which implies management is prioritizing balance-sheet repair and integration over returning cash. That is sensible with 5.04x debt/EBITDA, but it also limits near-term per-share support despite the old $1B repurchase authorization approved in 2024.
Management Execution & Track Record
Management's execution is mixed but improving. In the 2024 Q3 call, the company cut FY24 organic growth to 0%-1%, guided adjusted operating margin to 28.0%-28.5%, adjusted EPS to $4.83-$4.87, and free cash flow to about $550M, while acknowledging that "the path to normalization may take a little longer than previously expected" because instruments, especially in China, were weak. Since then, the company has delivered a strong beat cadence with 8 straight EPS beats, and the latest 2026 Q2 call showed enough improvement for management to raise FY26 organic growth to 4%-5% and adjusted EPS to $5.30-$5.40. That said, the strategy has not changed dramatically. It is still the same playbook of diagnostics resilience offsetting uneven life sciences demand, now helped by ACD/Labs and some better pharma/biotech spending. Credibility is decent on margins and EPS, but less strong on clean growth quality because Q2 included one-time tax timing and $16M of tariff refunds, while Life Sciences still posted -3% organic growth.
Positioning & Flows
Ownership is very concentrated, with the top three institutions at 95.4% and insiders just 0.4%, which can amplify moves when expectations shift. Short interest is not extreme but meaningful at 6.17%, or 6.3M shares and 4.1 days to cover, so there is some squeeze fuel, especially after the stock's 41.55% three-month move. Options positioning is flagged as positive gamma, which usually dampens near-term volatility rather than signaling a fresh upside squeeze setup.
Bull Case
- Management raised FY26 organic growth to 4%-5% from 3%-4%, with CEO stating, "Consequently, we are now expecting total company organic growth this year of 4% to 5%, up from our prior 3% to 4% outlook."
- Q2 execution was strong: $711M revenue, 3% organic growth, $1.41 adjusted EPS versus $1.21 street, and 29.3% adjusted operating margin versus the 27% outlook.
- Diagnostics is carrying the story, up 11% organic in Q2, while high-content screening order velocity exceeded production capacity and built backlog into 2H.
- The earnings track record is credible, with 8 straight EPS beats, including +16.5%, +8.3%, and +13.3% beats in the last eight quarters.
Bear Case
- The valuation is extreme for the growth on offer: 61.2x P/E on FY2025 EPS and peer dispersion is wide at 3.7x, weakening the case that peer multiples justify the stock.
- FY2025 fundamentals were not strong enough to support this price, with revenue up only 1.8% YoY and operating margin down to 13.5% from 14.9%.
- Q2 upside was not fully clean. Management cited $16M tariff refunds and tax timing, and specifically noted that the tax benefit reverses in Q4.
- Life Sciences remains uneven, down 3% organic in Q2, with software off about 20% on contract timing and capacity constraints still limiting upside.
Valuation & Price Target
Engine price target $84.57 (-39.7% vs current), Low confidence.
- P/E Multiple: $44.06 (28% weight)
- P/S Multiple: $82.23 (20% weight)
- Quality-adjusted: $143.55 (20% weight)
- DCF: $84.72 (8% weight)
This analysis stays aligned with the quant baseline of SELL, but with Medium rather than low conviction because operations have improved more than a pure trailing view implies. The reason not to diverge bullishly is valuation: the stock is at $140.19, effectively the 52-week high, against an engine target of $84.57, and it trades at 61.2x FY2025 EPS and 4.93x sales versus peers at 25.9x and 3.2x. Forward numbers are better, with $5.30-$5.40 adjusted EPS and 4%-5% organic growth, but that still leaves the shares around 26x forward adjusted EPS while leverage sits at 5.04x debt/EBITDA and FY2025 free cash flow was only $0.2B. Sell-side consensus sits at Strong Buy, but that is a low-signal backdrop here because the disagreement is mostly about how much premium this quality of growth deserves, not whether the quarter was good.
Risk Assessment
Risk score 51/100 (Moderate). The biggest risk to a bearish stance is that Diagnostics sustains double-digit growth and Life Sciences rebounds fast enough for investors to look through the current 61.2x multiple.
The Bottom Line
Rated SELL, Medium conviction. RVTY is executing better than it was two years ago, but the stock has already repriced that improvement and then some. A company guiding 4%-5% organic growth and carrying 5.04x debt/EBITDA should not comfortably command 61.2x FY2025 EPS at the 52-week high. The bearish call would change if the company proves that Diagnostics strength can lift whole-company growth sustainably above the current guide while Life Sciences recovers without one-time earnings support. Until that evidence is in the numbers, the stock looks priced for more than the business has earned.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr